REGULATORY BRIEFING

Egypt Pharma Localization: Import Bans, API Targets and a Fast Track for Export Plants

Egypt now makes about 91% of the medicines its people use, and its regulator wants the rest. The Egyptian Drug Authority suspends imports once a local equivalent exists, is targeting the 50 APIs the country imports most, and fast-tracks approvals for plants that make for export. For multinationals, API suppliers and CDMOs, Egypt is becoming a market you serve from inside.

Egypt localization and Manufacturing for Export: latest updates

Egypt localization and Manufacturing for Export at a glance

RegionEgypt
InstrumentsEDA import substitution for products with local equivalents; API localization program; Manufacturing for Export framework; Investment and Export Incentives Guide; National Drug Policy 2026–2030
Legal statusIn force and applied by EDA
Key datesLocal equivalents list published January 13, 2026; $3 billion export target by 2030
Most exposedMultinationals importing into Egypt, API suppliers in India and China, Egyptian manufacturers and CDMOs with export capacity
Official sourceEgyptian Drug Authority
PharmaSource Score135 (rank 34)
Impact 5, Reach 3, Likelihood 9
Download the PharmaSource Regulatory Radar

What Egypt’s localization and Manufacturing for Export policies are

Egypt’s market reached about EGP 422 billion ($8.48 billion) in 2025, up 37% on 2024. A dollar shortage in 2024 left patients without imported medicines, and the government answered with policy that treats local production as health security. EDA, the regulator, pulls five levers:

Where Egypt’s localization drive stands

What Egypt’s localization policies mean for manufacturing and outsourcing

The finished-dose base is large; the chemistry underneath it is thin. Egypt has only five factories specializing in pharmaceutical raw materials, and Arab API’s chairman Ahmed Kilani said in January that Egypt imports over 90% of its raw materials. That gap shapes who wins:

  • Multinationals selling into Egypt: An imported product can lose its market once a local equivalent appears. Technology transfer to a local partner keeps it in: Sandoz and SEDICO are localizing five cancer medicines, and Bayer has partnered with Minapharm to make and export from Egypt.
  • Egyptian contract manufacturers: Local firms are leasing production lines to overseas companies, and pharma is among the sectors that rely most on contract manufacturing. Opella runs its Egyptian business through a dual-sourcing contract manufacturing model.
  • API suppliers in India and China: Egypt still needs their volume today. Over time, the top-50 program targets exactly the molecules they sell most, and EDA has not published the full list.
  • Biologics and plasma: Grifols has invested €280 million in Egypt and plans €180 million more from 2026 to 2029, though its plasma products are still made in Spain. The new EIPICO plant brings recombinant protein work onshore.
  • Sponsors supplying Africa: Faster export approvals and mutual recognition make Egyptian sites a route into African markets with smaller regulators.

For outsourcing leaders, the practical step is to check which imported products in Egypt now have, or could soon have, a local equivalent, and to line up a local manufacturing or licensing partner before EDA acts on them.

Why supporters back Egypt’s localization drive

“Cutting regulatory approval times by more than half through fast-track pathways.”

Ali El-Ghamrawy, chairman, Egyptian Drug Authority, on Manufacturing for Export (Business Monthly)
  • Supply security: Local plants kept chronic medicines on shelves when foreign currency ran short. EDA says local manufacturing now covers 92% to 94% of demand for essential and chronic medicines.
  • Foreign currency: Each localized product cuts the import bill. AmCham Egypt reports that localization replaced 208 imported drugs that had cost more than $732 million a year.
  • Export growth: Exports reached about $1.3 billion in 2025, up from $1.079 billion in 2024, and the 2026 target is $1.6 billion to $1.7 billion.
  • A regional hub: WHO Maturity Level 3 and mutual recognition give Egyptian approvals weight across Africa, where few countries make their own medicines.

Criticisms of Egypt’s localization drive

“Should not be measured simply by the number of locally manufactured products.”

Muhammad Nouh, R&D general manager, EIPICO, on localization (Arab Finance)

What’s next for Egypt’s localization drive

  • More local equivalents lists: EDA will add products as local makers develop them, with no fixed schedule.
  • API projects: Watch which of the top 50 APIs reach commercial production, and whether EDA publishes the list.
  • Grifols complex: The first phase of its industrial complex was due to open in October 2026, and Grifols targets collection capacity of up to 3 million liters of plasma a year by 2029.
  • Exports: Whether 2026 exports reach the $1.6 billion target will show if Manufacturing for Export is working.
  • Our score: The policy scores 135 (rank 34). Likelihood is 9 because EDA already applies the lists. Impact is 5 because import suspensions force local sourcing, and Reach stays at 3 because the rules bite only on products sold in Egypt.

Related articles

Tracking global policies and their impact on biopharma manufacturing
REGULATORY RADAR
Full tracker of regulation changing biopharma manufacturing and supply.
Free to access and updated daily.